{"title":"关于停止曲安奈德治疗瘢痕疙瘩和增生性疤痕的关注","authors":"Zahra Arabi , Omar Hausien , Norbert Kang","doi":"10.1016/j.bjps.2025.07.009","DOIUrl":null,"url":null,"abstract":"<div><div>Triamcinolone acetonide (TAC), a synthetic glucocorticoid, is commonly administered as an intralesional injection for patients who present in our clinics with keloid or hypertrophic scars (HTS). The use of TAC (i.e. Adcortyl® or Kenalog® supplied by Bristol-Myers-Squibb) for this purpose is also supported by many studies.<sup>1</sup> It therefore comes with great disappointment to learn the decision from Department of Health and Social Care to withdraw the license for use of Adcortyl® and Kenalog® in the UK, especially as there are limited studies evaluating the suitability of alternatives.<sup>1,3</sup> However, we encourage the investigation into the potential therapeutic effects of benzyl alcohol (15mg/ml), an excipient in Adcortyl® and Kenalog®, in the treatment of keloids and HTS in the future.<sup>5</sup></div></div>","PeriodicalId":50084,"journal":{"name":"Journal of Plastic Reconstructive and Aesthetic Surgery","volume":"108 ","pages":"Pages 8-9"},"PeriodicalIF":2.0000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Concerns about the discontinuation of triamcinolone acetonide in the management of keloid and hypertrophic scars\",\"authors\":\"Zahra Arabi , Omar Hausien , Norbert Kang\",\"doi\":\"10.1016/j.bjps.2025.07.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Triamcinolone acetonide (TAC), a synthetic glucocorticoid, is commonly administered as an intralesional injection for patients who present in our clinics with keloid or hypertrophic scars (HTS). The use of TAC (i.e. Adcortyl® or Kenalog® supplied by Bristol-Myers-Squibb) for this purpose is also supported by many studies.<sup>1</sup> It therefore comes with great disappointment to learn the decision from Department of Health and Social Care to withdraw the license for use of Adcortyl® and Kenalog® in the UK, especially as there are limited studies evaluating the suitability of alternatives.<sup>1,3</sup> However, we encourage the investigation into the potential therapeutic effects of benzyl alcohol (15mg/ml), an excipient in Adcortyl® and Kenalog®, in the treatment of keloids and HTS in the future.<sup>5</sup></div></div>\",\"PeriodicalId\":50084,\"journal\":{\"name\":\"Journal of Plastic Reconstructive and Aesthetic Surgery\",\"volume\":\"108 \",\"pages\":\"Pages 8-9\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Plastic Reconstructive and Aesthetic Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1748681525004255\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Plastic Reconstructive and Aesthetic Surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1748681525004255","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
摘要
曲安奈德(TAC)是一种合成糖皮质激素,通常用于瘢痕疙瘩或肥厚性疤痕(HTS)患者的病灶内注射。为此目的使用TAC(即百时美施贵宝提供的Adcortyl®或Kenalog®)也得到了许多研究的支持因此,得知英国卫生和社会保障部(Department of Health and Social Care)决定撤销Adcortyl®和Kenalog®在英国的使用许可,尤其是在评估替代品适用性的研究有限的情况下,我们感到非常失望。然而,我们鼓励对苯甲醇(15mg/ml) (Adcortyl®和Kenalog®中的一种赋形剂)在治疗瘢痕疙瘩和HTS中的潜在治疗效果进行研究
Concerns about the discontinuation of triamcinolone acetonide in the management of keloid and hypertrophic scars
Triamcinolone acetonide (TAC), a synthetic glucocorticoid, is commonly administered as an intralesional injection for patients who present in our clinics with keloid or hypertrophic scars (HTS). The use of TAC (i.e. Adcortyl® or Kenalog® supplied by Bristol-Myers-Squibb) for this purpose is also supported by many studies.1 It therefore comes with great disappointment to learn the decision from Department of Health and Social Care to withdraw the license for use of Adcortyl® and Kenalog® in the UK, especially as there are limited studies evaluating the suitability of alternatives.1,3 However, we encourage the investigation into the potential therapeutic effects of benzyl alcohol (15mg/ml), an excipient in Adcortyl® and Kenalog®, in the treatment of keloids and HTS in the future.5
期刊介绍:
JPRAS An International Journal of Surgical Reconstruction is one of the world''s leading international journals, covering all the reconstructive and aesthetic aspects of plastic surgery.
The journal presents the latest surgical procedures with audit and outcome studies of new and established techniques in plastic surgery including: cleft lip and palate and other heads and neck surgery, hand surgery, lower limb trauma, burns, skin cancer, breast surgery and aesthetic surgery.